Evidence mapPaperPMID 41936096Full record

ReviewRheumatology (Oxford, England)2026

Primary myocardial involvement in systemic sclerosis: pathophysiology, clinical manifestations and advances in cardiac imaging.

Maya H Buch

Abstract readReview
In one paragraph

Review in Rheumatology (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Arrythmias in Autoimmune Diseases: Immune-Mediated Mechanisms and Management.Journal of cardiovascular development and disease · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Maya H BuchCentre for Musculoskeletal Research, University of Manchester, Manchester, UK.ORCID 0000-0002-8962-5642

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Systemic sclerosis (SSc) is a rare systemic autoimmune rheumatic disease associated with the highest cardiovascular risk among autoimmune conditions. Beyond pulmonary complications, primary heart involvement (pHI) represents a major cause of morbidity and mortality yet frequently remains asymptomatic and under-recognized. Microvascular dysfunction, myocardial inflammation and progressive interstitial and replacement fibrosis are central mechanisms. Clinical manifestations range from myocarditis to heart failure, arrhythmias and sudden cardiac death, while subclinical myocardial involvement is common and prognosis remains poor once overt disease develops. Advanced cardiovascular imaging, particularly cardiovascular magnetic resonance, has transformed detection through sensitive assessment of myocardial structure, function and myocardial tissue characterization, while PET may offer complementary insights. However, optimal screening strategies, imaging application and disease-specific therapies remain unmet needs. This review summarizes current understanding of SSc-pHI pathophysiology, clinical presentations and management, with a focus on the evolving role of multimodality imaging in early detection and risk stratification.

Indexed as

Cardiac Imaging TechniquesCardiomyopathiesScleroderma, SystemicHumansMagnetic Resonance ImagingMyocardiumautoimmune rheumatic diseasecardiac MRIechocardiographymyocardial fibrosismyocardial inflammationprimary heartsystemic sclerosis

Identifiers

PMID41936096
PMCPMC13110723

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.